Suggested remit: To appraise the clinical and cost effectiveness of vanzacaftor–tezacaftor–deutivacaftor within its marketing authorisation for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6372

Project Team

Project lead scopingta@nice.org.uk

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
17 September 2024 - 15 October 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6372
17 September 2024 In progress. Scoping commencing
17 September 2024 In progress. Scoping commencing
26 July 2024 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
12 October 2023 Topic selection

For further information on our processes and methods, please see our CHTE processes and methods manual